Strides Sells Australian Business To Arrow-Apotex Merger
Strides Pharma Science has agreed to sell its entire Australian business, including its local Arrow unit, to the Arrow-Apotex merged entity known as ‘Arrotex’, as the firm concentrates its efforts in the US and Canada.
You may also be interested in...
Strides Says Forsteo Biosimilar ‘Significant Product’, Seeks New Minority Investor In Stelis
Strides sees Kauliv, a biosimilar to Eli Lilly’s Forsteo, as a ‘significant’ but ‘not a massive product’ as it prepares to register it in multiple countries post a positive opinion from EMA. Meanwhile, more clarity on fund raising for Stelis is expected by March 2023 even as the regulatory timeline for a COVID-19 vaccine from Akston is extended by 2-3 months
New Faces Feature In Industry Top 50
In the third and final part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies, one or two new entrants appeared towards the bottom of the top 50.
Strides Grows In Central Europe Through Fairmed Deal
Strides Pharma Science has acquired a majority stake in Swiss generics firm Fairmed Healthcare in a move to bolster its presence in central Europe. The acquisition marks the latest in a string of transactions by the Indian firm.